These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9194482)

  • 1. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module.
    Evans WK
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-56-S7-63. PubMed ID: 9194482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer.
    Evans WK
    Semin Oncol; 1996 Oct; 23(5 Suppl 10):82-9. PubMed ID: 8893888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
    Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.
    Copley-Merriman C; Corral J; King K; Whiteside R; Voi M; Dorr FA; McDonald RC
    Lung Cancer; 1996 Feb; 14(1):45-61. PubMed ID: 8696720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer.
    Szczepura A
    Lung Cancer; 2002 Nov; 38 Suppl 2():S21-8. PubMed ID: 12431825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer.
    Tennvall GR; Fernberg JO
    Med Oncol; 1998 Jul; 15(2):129-36. PubMed ID: 9789222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
    Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C; Perrone F; Di Maio M; Bradbury PA; Evans WK
    Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
    Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
    Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of the pharmacoeconomic research on gemcitabine in the treatment of advanced non-small cell lung cancer.
    Minshall ME; Liepa AM
    Am J Manag Care; 1998 Nov; 4(11):1591-602. PubMed ID: 10338905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
    Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
    J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review.
    Hansen HH; Sørensen JB
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-38-S7-41. PubMed ID: 9194478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer.
    Koch P; Johnson N; van Schaik J; Andersen S; Blatter J; Bosanquet N; Copley-Merriman K; Drings P
    Anticancer Drugs; 1995 Dec; 6 Suppl 6():49-54. PubMed ID: 8718425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
    Earle CC; Evans WK
    Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of combined modality interventions for stage III non-small-cell lung cancer.
    Evans WK; Will BP; Berthelot JM; Earle CC
    J Clin Oncol; 1997 Sep; 15(9):3038-48. PubMed ID: 9294466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer.
    Lees M; Aristides M; Maniadakis N; McKendrick J; Botwood N; Stephenson D
    Pharmacoeconomics; 2002; 20(5):325-37. PubMed ID: 11994042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent gemcitabine in non-small cell lung cancer: the French experience.
    Le Chevalier T; Gottfried M
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-47-S7-49. PubMed ID: 9194480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
    Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
    Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economics of lung cancer management in Canada.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Lung Cancer; 1996 Feb; 14(1):19-29. PubMed ID: 8696718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.